Page 58 - 2019_02-Haematologica-web

A. Contejean et al.
patients, overall mortality of AA in elderly is very encour- aging. Age, per se, is not a limiting factor to AA treatment with ATG-CsA; this regimen should be used as first-line treatment in elderly patients if they have a good perform- ance status and low comorbidity index score. Among patients with adverse performance status, or comorbidi- ties contra-indicating the use of ATG, CsA alone or in combination may be safely used. Other treatment strate- gies might be reserved for later courses of treatments. In addition, supportive care may have a great impact on sur- vival in this population. These results require confirma- tion through prospective data specifically collected in this population with extended follow up.
Acknowledgments
Authors would like to thank HPN-France association for help- ing fund this study, David Williams for editorial assistance and all who participated to data collection: Audrey Aleme, Marie Balsat, Claire Blanchard-Delaunay, Julie Bruneau, Axelle Canard, Cécile Chabrot, Sylvain Chantepie, Régis Costello, Luc Darnige, Eric Deconinck, Stéphane Girault, Gaëlle Guillerm, Mathilde Hunault, Dominique Jacomy, Ingrid Lafon, Marielle Le Goff, Ollivier Legrand, Richard Lemal, Bruno Lioure, Marius Moldovan, Valérie Rebeix, Isabelle Roche-Lachaise, Célia Salanoubat, Andreea Sandu, Jose Miguel Torrerosa-Diaz and Aliénor Xhaard.
References
1. Young NS, Kaufman DW. The epidemiolo- gy of acquired aplastic anemia. Haematologica. 2008;93(4):489-492.
2. Modan B, Segal S, Shani M, Sheba C. Aplastic anemia in Isreal: evaluation of the etiological role of chloramphenicol on a community-wide basis. Am J Med Sci. 1975;270(3):441-445.
3. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;6023-30.
4. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518-523.
5. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987;70(6):1718-1721.
6. Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990;75(8):1646-1653.
7. Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive thera- py in older patients with aplastic anemia. Ann Intern Med. 1999;130(3):193-201.
8. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet Lond Engl. 2005;365(9471):1647- 1656.
9. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplas- tic syndromes and aplastic anemia: recom- mendations for a standardized approach. Haematologica. 2009;94(2):264-268.
10. Yoshizato T, Dumitriu B, Hosokawa K, et al. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35-47.
11. Kim S-Y, Lee J-W, Lee S-E, et al. The char- acteristics and clinical outcome of adult patients with aplastic anemia and abnor- mal cytogenetics at diagnosis. Genes Chromosomes Cancer. 2010; 49(9):844- 850.
12. Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (>60 years) with acquired aplastic anaemia treated
with immunosuppressive therapy. Br J
Haematol. 2008;143(5):738-743.
13. Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011.
Haematologica. 2017;102(10):1683-1690. 14. Tichelli A, Marsh JCW. Treatment of aplas- tic anaemia in elderly patients aged> 60 years. Bone Marrow Transplant.
2013;48(2):180-182.
15. Killick SB, Bown N, Cavenagh J, et al.
Guidelines for the diagnosis and manage- ment of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
16. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436.
17. Shin SH, Jeon YW, Yoon JH, et al. Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplanta- tion using fludarabine-based conditioning. Bone Marrow Transplant. 2016; 51(11):1456-1463.
18. Horowitz MM. Current status of allogene- ic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000; 37(1):30-42.
19. Devillier R, Dalle J-H, Kulasekararaj A, et al. Unrelated alternative donor transplanta- tion for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. Haematologica. 2016;101(7):884-890.
20. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow trans- plantation on acute mortality. Blood. 1976;48(1):63-70.
21. Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). Haematologica. 1994;79(5):438-444.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classify- ing prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
23. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity
index and score for risk adjustment in hos- pital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6):676-682.
24. Appelbaum FR, Barrall J, Storb R, et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987; 15(11):1134- 1139.
25. Hosokawa K, Sugimori N, Katagiri T, et al. Increased glycosylphosphatidylinositol- anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Haematol. 2015;95(3):230-238.
26. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87(7):515-526.
27. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81(5):418-422.
28. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical out- comes for cytogenetic abnormalities evolv- ing from aplastic anemia. Blood. 2002; 99(9):3129-3135.
29. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012; 120(6):1185-1196.
30. Dufour C, Svahn J, Bacigalupo A. Front- line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):174-177.
31. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79(10):2540-2546.
32. Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrom- bopag in patients with severe aplastic ane- mia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212-220.
33. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic ane- mia receiving antithymocyte globulin (ATG), cyclosporine, with or without G- CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011; 117(17):4434-4441.
262
haematologica | 2019; 104(2)